Pfizer and BioNTech Provide Updates on its Collaboration for Global COVID-19 Vaccine
Shots:
- BioNTech to receive $185M up front- including $72M cash & $113M equity investment- up to $563M as milestone making a total deal value $748M. The companies will equally share the development cost while Pfizer will fund 100% of development cost at the initial level and BioNTech will repay Pfizer its 50% share during the commercialization of the vaccine
- The two companies plan to jointly conduct clinical studies for the COVID-19 vaccine candidates initially in the US and EU with the expected initiation of the first clinical study as early as the end of Apr’2020
- BioNTech will provide multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program while Pfizer will contribute its global vaccine clinical research and development- regulatory- manufacturing and distribution infrastructure and capabilities
Click here to read full press release/ article | Ref: Pfizer | Image: Pfizer
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com